Cargando…

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharyya, Sudeepa, Ahmed, Ahmed T., Arnold, Matthias, Liu, Duan, Luo, Chunqiao, Zhu, Hongjie, Mahmoudiandehkordi, Siamak, Neavin, Drew, Louie, Gregory, Dunlop, Boadie W., Frye, Mark A., Wang, Liewei, Weinshilboum, Richard M., Krishnan, Ranga R., Rush, A. John, Kaddurah-Daouk, Rima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609722/
https://www.ncbi.nlm.nih.gov/pubmed/31273200
http://dx.doi.org/10.1038/s41398-019-0507-5
_version_ 1783432366909292544
author Bhattacharyya, Sudeepa
Ahmed, Ahmed T.
Arnold, Matthias
Liu, Duan
Luo, Chunqiao
Zhu, Hongjie
Mahmoudiandehkordi, Siamak
Neavin, Drew
Louie, Gregory
Dunlop, Boadie W.
Frye, Mark A.
Wang, Liewei
Weinshilboum, Richard M.
Krishnan, Ranga R.
Rush, A. John
Kaddurah-Daouk, Rima
author_facet Bhattacharyya, Sudeepa
Ahmed, Ahmed T.
Arnold, Matthias
Liu, Duan
Luo, Chunqiao
Zhu, Hongjie
Mahmoudiandehkordi, Siamak
Neavin, Drew
Louie, Gregory
Dunlop, Boadie W.
Frye, Mark A.
Wang, Liewei
Weinshilboum, Richard M.
Krishnan, Ranga R.
Rush, A. John
Kaddurah-Daouk, Rima
author_sort Bhattacharyya, Sudeepa
collection PubMed
description Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD(17)) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD(17) scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD(17). Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms.
format Online
Article
Text
id pubmed-6609722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66097222019-07-08 Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients Bhattacharyya, Sudeepa Ahmed, Ahmed T. Arnold, Matthias Liu, Duan Luo, Chunqiao Zhu, Hongjie Mahmoudiandehkordi, Siamak Neavin, Drew Louie, Gregory Dunlop, Boadie W. Frye, Mark A. Wang, Liewei Weinshilboum, Richard M. Krishnan, Ranga R. Rush, A. John Kaddurah-Daouk, Rima Transl Psychiatry Article Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD(17)) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD(17) scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD(17). Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms. Nature Publishing Group UK 2019-07-04 /pmc/articles/PMC6609722/ /pubmed/31273200 http://dx.doi.org/10.1038/s41398-019-0507-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bhattacharyya, Sudeepa
Ahmed, Ahmed T.
Arnold, Matthias
Liu, Duan
Luo, Chunqiao
Zhu, Hongjie
Mahmoudiandehkordi, Siamak
Neavin, Drew
Louie, Gregory
Dunlop, Boadie W.
Frye, Mark A.
Wang, Liewei
Weinshilboum, Richard M.
Krishnan, Ranga R.
Rush, A. John
Kaddurah-Daouk, Rima
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title_full Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title_fullStr Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title_full_unstemmed Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title_short Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
title_sort metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609722/
https://www.ncbi.nlm.nih.gov/pubmed/31273200
http://dx.doi.org/10.1038/s41398-019-0507-5
work_keys_str_mv AT bhattacharyyasudeepa metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT ahmedahmedt metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT arnoldmatthias metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT liuduan metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT luochunqiao metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT zhuhongjie metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT mahmoudiandehkordisiamak metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT neavindrew metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT louiegregory metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT dunlopboadiew metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT fryemarka metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT wangliewei metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT weinshilboumrichardm metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT krishnanrangar metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT rushajohn metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients
AT kaddurahdaoukrima metabolomicsignatureofexposureandresponsetocitalopramescitalopramindepressedoutpatients